Climb Bio Inc (CLYM) Stock Price, Quote & News

Company Profile

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclo...

Industry: Biotechnology

Sector: Healthcare

Phone: 866 857 2596

Website: climbbio.com

Address:

20 William Street, Suite 145, Wellesley Hills, United States

War1en_Callahan Jan. 7 at 8:48 PM

$CLYM The only thing that matters: compute is already ~40GW, projected ~500 TWh/yr by 2030, and the richest corps on Earth are spending trillions. Power is the new moat and speed is the weapon. Grids move slow, queues get ugly, turbines wait years… so you go behind-the-meter and keep shipping. This is where the real leverage is ⚡

0 · Reply

KingXamot Jan. 6 at 6:47 PM

$CLYM I acknowledge you.

0 · Reply

JFais Jan. 6 at 2:28 PM

$CLYM- Across The Biotech Universe: Climb Bio https://seekingalpha.com/instablog/440063-jonathan-faison/6244771-across-the-biotech-universe-clym?source=tweet

0 · Reply

peepthestamp Jan. 2 at 9:59 AM

$CLYM -Aged well🫡

0 · Reply

JohnTrack Dec. 31 at 11:35 PM

$CLYM hanging around this chart!

0 · Reply

JohnTrack Dec. 31 at 9:23 PM

$CLYM complaint filed against Alumis Inc https://www.rapidticker.com/news/clym-sec-filing-08d990

0 · Reply

SuperGreenToday Dec. 23 at 10:28 PM

$CLYM

0 · Reply

Alidrisi Dec. 23 at 5:25 AM

$CLYM +64%

0 · Reply

Ralphbeach Dec. 23 at 3:09 AM

$CLYM I was all over this in September. Opportunities are like sunrises. If you wait too long, you miss them. This is going to go a lot higher.

0 · Reply

mz101 Dec. 23 at 2:34 AM

$CLYM why the boost pm?

0 · Reply

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 6, 2025, 7:01 AM EST - 2 months ago

Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 3, 2025, 7:00 AM EST - 2 months ago

Climb Bio to Present at Upcoming Investor Conferences

Oct 21, 2025, 7:00 AM EDT - 2 months ago

Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy

Oct 17, 2025, 7:00 AM EDT - 2 months ago

Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025

Oct 1, 2025, 7:00 AM EDT - 3 months ago

Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer

Sep 29, 2025, 7:00 AM EDT - 3 months ago

Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN

Sep 4, 2025, 7:00 AM EDT - 4 months ago

Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025

Aug 25, 2025, 2:41 PM EDT - 4 months ago

UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences

Aug 25, 2025, 7:00 AM EDT - 4 months ago

Climb Bio to Present at Upcoming September 2025 Investor Conferences

Aug 12, 2025, 7:00 AM EDT - 5 months ago

Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

May 14, 2025, 7:00 AM EDT - 8 months ago

Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 1, 2025, 7:00 AM EDT - 10 months ago

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Mar 27, 2025, 7:00 AM EDT - 10 months ago

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 25, 2025, 4:05 PM EDT - 10 months ago

Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

Feb 24, 2025, 7:00 AM EST - 11 months ago

Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

Feb 4, 2025, 7:00 AM EST - 1 year ago

Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 9, 2025, 7:00 AM EST - 1 year ago

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

Dec 19, 2024, 7:00 AM EST - 1 year ago

Climb Bio to be Added to the Nasdaq Biotechnology Index

Nov 12, 2024, 4:05 PM EST - 1 year ago

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 11, 2024, 7:00 AM EST - 1 year ago

Climb Bio Appoints Douglas E. Williams, Ph.D.

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

Oct 11, 2024, 12:30 PM EDT - 1 year ago

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

Oct 4, 2024, 7:00 AM EDT - 1 year ago

Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

Oct 3, 2024, 10:00 AM EDT - 1 year ago

Climb Bio to Host Virtual Investor Event on October 15, 2024

Oct 2, 2024, 9:00 AM EDT - 1 year ago

Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.

Sep 11, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

Aug 26, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces Additions to its Leadership Team

Aug 14, 2024, 6:05 AM EDT - 1 year ago

Eliem Therapeutics Reports Second Quarter Financial Results

Jun 28, 2024, 1:58 PM EDT - 1 year ago

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Jun 28, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Jun 27, 2024, 4:01 PM EDT - 1 year ago

Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Jul 20, 2023, 6:57 AM EDT - 2 years ago

Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself

Jul 20, 2023, 6:45 AM EDT - 2 years ago

Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

May 11, 2023, 4:10 PM EDT - 2 years ago

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

Mar 6, 2023, 4:10 PM EST - 3 years ago

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

Feb 9, 2023, 4:01 PM EST - 3 years ago

Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition

Nov 30, 2022, 7:00 AM EST - 3 years ago

Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference

Nov 14, 2022, 6:10 AM EST - 3 years ago

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

Nov 8, 2022, 7:00 AM EST - 3 years ago

Eliem Therapeutics to Participate at Two Upcoming Investor Conferences

Oct 5, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics Provides Update on Pipeline Progress

Aug 15, 2022, 6:10 AM EDT - 3 years ago

Eliem Therapeutics Reports Second Quarter Financial and Business Highlights

Aug 2, 2022, 9:33 AM EDT - 3 years ago

Eliem's stock slides 20% after saying it will discontinue development of pain treatment

Aug 2, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics Provides ETX-810 Program Update

Jul 18, 2022, 7:00 AM EDT - 3 years ago

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

Jul 7, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022

War1en_Callahan Jan. 7 at 8:48 PM

0 · Reply

KingXamot Jan. 6 at 6:47 PM

$CLYM I acknowledge you.

0 · Reply

JFais Jan. 6 at 2:28 PM

$CLYM- Across The Biotech Universe: Climb Bio https://seekingalpha.com/instablog/440063-jonathan-faison/6244771-across-the-biotech-universe-clym?source=tweet

0 · Reply

peepthestamp Jan. 2 at 9:59 AM

$CLYM -Aged well🫡

0 · Reply

JohnTrack Dec. 31 at 11:35 PM

$CLYM hanging around this chart!

0 · Reply

JohnTrack Dec. 31 at 9:23 PM

$CLYM complaint filed against Alumis Inc https://www.rapidticker.com/news/clym-sec-filing-08d990

0 · Reply

SuperGreenToday Dec. 23 at 10:28 PM

$CLYM

0 · Reply

Alidrisi Dec. 23 at 5:25 AM

$CLYM +64%

0 · Reply

Ralphbeach Dec. 23 at 3:09 AM

$CLYM I was all over this in September. Opportunities are like sunrises. If you wait too long, you miss them. This is going to go a lot higher.

0 · Reply

mz101 Dec. 23 at 2:34 AM

$CLYM why the boost pm?

0 · Reply

Dandomski Dec. 23 at 12:59 AM

$CLYM how high will this go? Bought 2k shares at 1.98

0 · Reply

donthateme Dec. 22 at 6:00 PM

$FJET $CLYM now moving up fast. Still low volume. Still in my $FJET for only 500 shares but up 50%! Woot woot

0 · Reply

Alidrisi Dec. 22 at 6:00 PM

$CLYM + 47% ,,, still

0 · Reply

John_week Dec. 22 at 5:56 PM

$CLYM

0 · Reply

www_larval_com Dec. 22 at 2:38 PM

$NBY 10%[8%] $VELO -10%[14%] $FJET 6%[34%] $IVVD 5%[18%] $CLYM -5%[6%] most notable movement within the first minutes of trading.

0 · Reply

Ric_1M Dec. 21 at 1:50 PM

$NBY $CLYM $CPAC $KYTX $RADX "Optimism is the faith that leads to achievement. Nothing can be done without hope and confidence." Helen Keller

1 · Reply

StockScanners Dec. 20 at 6:45 PM

$CLYM reached 4.82

0 · Reply

StockScanners Dec. 20 at 6:36 PM

$CLYM reached 4.60

0 · Reply

SwingTradesOnly Dec. 19 at 5:09 PM

$CLYM watching here. took profits. yesterday = spinning top candlestick = indecision. today can't hold gains. might (?) retrace to EMA(8) around 3.70 or .236 fib retrace at 4.09

0 · Reply

SwingTradesOnly Dec. 18 at 11:02 PM

$CLYM last two days

0 · Reply

SwingTradesOnly Dec. 18 at 5:09 PM

$CLYM or not. low volume decline, still way up. bull flag?

0 · Reply

SwingTradesOnly Dec. 18 at 2:53 PM

$CLYM 👀

0 · Reply

Market Cap	255.69M
Revenue (ttm)	0.00
Net Income (ttm)	-73.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	631,600
Avg Vol	1,334,670
Day's Range	N/A - N/A
Shares Out	68.18M
Stochastic %K	49%
Beta	-0.16
Analysts	Strong Sell
Price Target	$9.60